Why the study?
Diabetes mellitus seems to affect the efficacy of ticagrelor and prasugrel in patients with ACS.
Does ticagrelor improve efficacy compared to prasugrel in patients with acute coronary syndromes and diabetes mellitus?
Does ticagrelor improve efficacy compared to prasugrel in patients with acute coronary syndromes and diabetes mellitus?
Ticagrelor and prasugrel demonstrate comparable efficacy in patients with acute coronary syndromes and diabetes mellitus.
Answers are grounded in this paper and cite their sources.
Either ticagrelor or prasugrel may be used in ACS with diabetes; extends RCT evidence of equivalence to this subgroup.
DM seems to affect the efficacy of ticagrelor and prasugrel in patients with ACS. In patients with DM, the efficacy of ticagrelor was comparable with that of prasugrel. (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome [ISAR-REACT 5]; NCT01944800).
No takes yet. Share an insight, caveat, or question.
Ndrepepa et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: